Skip to content

Participate in our active studies Subscribe to our Mailing List

AB Science

Masitinib and AB8939 – Two compounds with breakthrough mechanism of action

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

Search:

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

AB Science Corporate Presentation

You are here:

Home
Investor Relations
AB Science Corporate Presentation

AB Science Corporate Presentation

Post navigation

PreviousPrevious post:AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA NextNext post:Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities

Related Posts

Governance
May 9, 2018

General Meeting preparatory documents
May 6, 2018

Other information
May 5, 2018

Frequently Asked Questions
May 1, 2018

Search

Search:

Recent Posts

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
Summary of the live webcast held on March 4, 2024, providing an update on AB Science development
Two financial analysis firms initiate coverage of AB Science
AB Science webcast of March 4, 2024
Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

AB SCIENCE
HEADQUARTER

3, Avenue George V – 75008 PARIS – FRANCE
Tel. : +33 (0)1 47 20 00 14
Fax. : +33 (0)1 47 20 24 11

GENERAL INQUIRIES

contact@ab-science.com

PRODUCT INQUIRIES

masivet@ab-science.com

JOB INQUIRIES

careers@ab-science.com

CLINICAL INQUIRIES

clinical@ab-science.com

MEDIA / FINANCIAL INQUIRIES

investors@ab-science.com

PHARMACOVIGILANCE

pharmacovigilance@ab-science.com
Fax : +33 1 47 20 10 82

© AB Science – All right reserved